Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 2/20 | 0.60 |
| ▸ | FNTB | P49356 | 2/20 | 0.60 |
| ▸ | CRYAB | P02511 | 4/20 | 0.39 |
| ▸ | CRYAA | P02489 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.33 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29934605 | 0.88 | FNTA (0.77) | FNTAFNTBCRYABCRYAAUSP2 | |
| SCHEMBL29934612 | 0.83 | FNTA (0.44) | FNTAFNTBCRYABCRYAAACHE | |
| SCHEMBL30584473 | 0.79 | FNTA (0.46) | FNTAFNTBCRYABCRYAAACHE | |
| SCHEMBL29934953 | 0.77 | FNTA (0.46) | FNTAFNTBCRYABCRYAAACHE | |
| Clavaric Acid SCHEMBL8897544 | 0.75 | FNTA (1.00) | FNTAFNTBCRYABCRYAAACHE | |
| Clavaric Acid SCHEMBL3471580 | 0.75 | FNTA (1.00) | FNTAFNTBCRYABCRYAAACHE | |
| SCHEMBL23699009 | 0.74 | FNTA (0.45) | FNTAFNTBCRYABCRYAAACHE | |
| SCHEMBL29375258 | 0.74 | FNTA (0.45) | FNTAFNTBCRYABCRYAAACHE | |
| Hebelomic Acid A SCHEMBL15944444 | 0.70 | FNTA (0.36) | FNTAFNTB | |
| Hebelomic Acid A SCHEMBL20035914 | 0.70 | FNTA (0.36) | FNTAFNTB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20220291237-A1 | Gene Expression Inflammatory Age and Its Uses | Edifice Health, Inc. (US) | 2022-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | FNTA 1865/4885FNTB 3113/4885CRYAB 630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.